An update in CLL from EHA 2020
Jul 14, 2020•7 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
During the 25th European Hematology Association (EHA) Annual Congress, the Lymphoma Hub spoke to Susan O'Brien, University of California Irvine, Orange, US, who discussed the latest updates on chronic lymphocytic leukemia (CLL) from EHA 2020.
Highlights in CLL from this year's virtual EHA Annual Congress include
1. Update (~39 months) from the CLL-14 trial (NCT02242942), comparing the safety and efficacy of obinutuzumab + venetoclax versus obinutuzumab + chlorambucil in patients with treatment-naïve CLL
2. Update from the CAPTIVATE trial (NCT02910583) evaluating ibrutinib + venetoclax in patients with treatment-naïve CLL
3. Acalabrutinib for the treatment of relapsed CLL
Hosted on Acast. See acast.com/privacy for more information.
For the best experience, listen in Metacast app for iOS or Android